Empagliflozin vs Osimertinib
Empagliflozin vs Osimertinib: Overview
This comparison examines the pharmacological differences between Empagliflozin and Osimertinib.
Mechanism of Action
Empagliflozin: Selective SGLT2 inhibitor reducing renal glucose reabsorption.
Osimertinib: Third-generation irreversible EGFR TKI targeting T790M resistance mutation and activating mutations.
Pharmacokinetics
Half-life: Empagliflozin β 12.4 hours; Osimertinib β 48 hours.
Chemical Properties
Molecular Formula: Empagliflozin β C23H27ClO7; Osimertinib β C28H33N7O2.
Molecular Weight: Empagliflozin β 450.9100 g/mol; Osimertinib β 499.6050 g/mol.
Type: Empagliflozin β Small molecule; Osimertinib β Small molecule.